1. 1. Sung H, Ferlay J, Siegel RL, et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3): 209-249. [DOI:10.3322/caac.21660] [PMID]

2. Ray-Coquard I, Pautier P, Pignata S, et al. (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med, 381(25): 2416-2428. [DOI:10.1056/NEJMoa1911361] [PMID]

3. Gogineni V, Morand S, Staats H, et al. (2021) Current ovarian cancer maintenance strategies and promising new developments. J Cancer, 12(1): 38-53. [DOI:10.7150/jca.49406] [PMID] []

4. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. (2021) Ovarian cancer, version 2.2020, NCCNclinical practice guidelines in oncology. J Natl Compr Canc Netw, 19(2): 191-226.

5. Vergote I, Coens C, Nankivell M, et al. (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol, 19(12): 1680-1687. [DOI:10.1016/S1470-2045(18)30566-7]

6. Coleridge SL, Bryant A, Kehoe S, Morrison J (2021) Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev, 7(7): Cd005343. [DOI:10.1002/14651858.CD005343.pub6] [PMID] []

7. Eshaghi M (2020) The effect of pain management on pain reduction in women with breast cancer. Sjmshm, 2(2): 1-5. [DOI:10.29252/sjmshm.2.2.1]

8. Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer, 6(12): 924-935. [DOI:10.1038/nrc2013] [PMID]

9. Xiao Y and Yu D (2021) Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther, 221: 107753. [DOI:10.1016/j.pharmthera.2020.107753] [PMID] []

10. Schumacher TN, Thommen DS (2022) Tertiary lymphoid structures in cancer. Science, 375(6576): eabf9419. [DOI:10.1126/science.abf9419] [PMID]

11. Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA (2020) Tertiary lymphoid structures in cancer - considerations for patient prognosis. Cell Mol Immunol, 17(6): 570-575. [DOI:10.1038/s41423-020-0457-0] [PMID] []

12. Cottrell TR, Thompson ED, Forde PM, et al. (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol, 29(8): 1853-1860. [DOI:10.1093/annonc/mdy218] [PMID] []

13. Vanhersecke L, Brunet M, Guégan JP, et al. (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer, 2(8): 794-802. [DOI:10.1038/s43018-021-00232-6] [PMID] []

14. Yang M, Lu J, Zhang G, et al. (2021) CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer, 9(1). [DOI:10.1136/jitc-2020-001136] [PMID] []

15. Amini J and Hasanramezani A (2022) AAK1 circular regulates neuronal development by interacting with miR-132, miR-146a and miR484. Alkhass, 4(4): 1-4. [DOI:10.47176/alkhass.4.4.1]

16. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer, 19(6): 307-325. [DOI:10.1038/s41568-019-0144-6] [PMID]

17. Lu H, Lou H, Wengert G, et al. (2023) Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep Med, 4(7): 101092. [DOI:10.1016/j.xcrm.2023.101092] [PMID] []

18. Taminau J, Meganck S, Lazar C, et al. (2012) Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics, 13: 335. [DOI:10.1186/1471-2105-13-335] [PMID] []

19. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics, 8(1): 118-127. [DOI:10.1093/biostatistics/kxj037] [PMID]

20. McEligot AJ, Poynor V, Sharma R, Panangadan A (2020) Logistic LASSO Regression for Dietary Intakes and Breast Cancer. Nutrients, 12(9). [DOI:10.3390/nu12092652] [PMID] []

21. Becht E, Giraldo NA, Lacroix L, et al. (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol, 17(1): 218. https://doi.org/10.1186/s13059-016-1113-y [DOI:10.1186/s13059-016-1070-5] [PMID] []

22. Elies A, Rivière S, Pouget N, et al. (2018) The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther, 18(6): 555-566. [DOI:10.1080/14737140.2018.1458614] [PMID]

23. Javellana M, Eckert MA, Heide J, et al. (2022) Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer. Cancer Res, 82(1): 169-176. [DOI:10.1158/0008-5472.CAN-21-1467] [PMID] []

24. Dieu-Nosjean MC, Giraldo NA, Kaplon H, et al. (2016) Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev, 271(1): 260-275. [DOI:10.1111/imr.12405] [PMID]

25. Feng H, Yang F, Qiao L, et al. (2021) Prognostic significance of gene signature of tertiary lymphoid structures in patients with lung adenocarcinoma. Front Oncol, 11: 693234. [DOI:10.3389/fonc.2021.693234] [PMID] []

26. An Y, Sun JX, Xu MY, et al. (2022) Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. Front Immunol, 13: 1049884. [DOI:10.3389/fimmu.2022.1049884] [PMID] []

27. Swanson K, Wu E, Zhang A, Alizadeh AA, Zou J (2023) From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell, 186(8): 1772-1791. [DOI:10.1016/j.cell.2023.01.035] [PMID]

28. Zhang L, Wu X, Fan X, Ai H (2023) MUM1L1 as a tumor suppressor and potential biomarker in ovarian cancer: Evidence from bioinformatics analysis and basic experiments. Comb Chem High Throughput Screen, 26(14): 2487-2501. [DOI:10.2174/1386207326666230301141912] [PMID]

29. Zhao E, Gao K, Xiong J, et al. (2023) The roles of FXYD family members in ovarian cancer: an integrated analysis by mining TCGA and GEO databases and functional validations. J Cancer Res Clin Oncol. [DOI:10.1007/s00432-023-05445-z] [PMID]

30. Zeng B, Yuan C, Yang X, Atkin SL, Xu SZ (2013) TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr Cancer Drug Targets, 13(1): 103-116. [DOI:10.2174/156800913804486629]

31. Chetry M, Li S, Liu H, Hu X, Zhu X (2018) Prognostic values of aquaporins mRNA expression in human ovarian cancer. Biosci Rep, 38(2). [DOI:10.1042/BSR20180108] [PMID] []

32. Bijsmans IT, Smits KM, de Graeff P, et al. (2011) Loss of serpinA5 protein expression is associated with advanced-stage serous ovarian tumors. Mod Pathol, 24(3): 463-470. [DOI:10.1038/modpathol.2010.214] [PMID]

33. Liang L, Li J, Yu J, et al. (2022) Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer. Cancer Cell Int, 22(1):118. [DOI:10.1186/s12935-022-02502-4] [PMID] []

34. Kandalaft LE, Dangaj Laniti D, Coukos G (2022) Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer, 22(11):640-656. [DOI:10.1038/s41568-022-00503-z] [PMID]

35. Hornburg M, Desbois M, Lu S, et al. (2021) Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell, 39(7): 928-944.e6. [DOI:10.1016/j.ccell.2021.04.004] [PMID]

36. Li X, Liang W, Zhao H, et al. (2021) Immune cell infiltration landscape of ovarian cancer to identify prognosis and immunotherapy-related genes to aid immunotherapy. Front Cell Dev Biol, 9: 749157. [DOI:10.3389/fcell.2021.749157] [PMID] []